primary abs against cd45 2 Search Results


cd45 2 percp cy5 5 thermofisher  (Thermo Fisher)
94
Thermo Fisher cd45 2 percp cy5 5 thermofisher
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Cd45 2 Percp Cy5 5 Thermofisher, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2 percp cy5 5 thermofisher/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
cd45 2 percp cy5 5 thermofisher - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cd45 2 apc fire750  (Revvity)
99
Revvity cd45 2 apc fire750
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Cd45 2 Apc Fire750, supplied by Revvity, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2 apc fire750/product/Revvity
Average 99 stars, based on 1 article reviews
cd45 2 apc fire750 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
cd45 2 antibody  (Thermo Fisher)
86
Thermo Fisher cd45 2 antibody
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Cd45 2 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2 antibody/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
cd45 2 antibody - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier
anti-cd45.2-apc (104-apc)  (Thermo Fisher)
90
Thermo Fisher anti-cd45.2-apc (104-apc)
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Anti Cd45.2 Apc (104 Apc), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd45.2-apc (104-apc)/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-cd45.2-apc (104-apc) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cd45 2  (Cytek Biosciences)
90
Cytek Biosciences cd45 2
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Cd45 2, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45 2/product/Cytek Biosciences
Average 90 stars, based on 1 article reviews
cd45 2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
f4/80 apc  (Thermo Fisher)
90
Thermo Fisher f4/80 apc
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
F4/80 Apc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/f4/80 apc/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
f4/80 apc - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
apc-cy™7 mouse anti-mouse cd45.2  (Becton Dickinson)
90
Becton Dickinson apc-cy™7 mouse anti-mouse cd45.2
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Apc Cy™7 Mouse Anti Mouse Cd45.2, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc-cy™7 mouse anti-mouse cd45.2/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
apc-cy™7 mouse anti-mouse cd45.2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti cd45 2  (Cytek Biosciences)
92
Cytek Biosciences anti cd45 2
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
Anti Cd45 2, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd45 2/product/Cytek Biosciences
Average 92 stars, based on 1 article reviews
anti cd45 2 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
0454 total leukocytes  (Cytek Biosciences)
93
Cytek Biosciences 0454 total leukocytes
(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from <t>CD45</t> congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, <t>CD45.2)</t> and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).
0454 Total Leukocytes, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/0454 total leukocytes/product/Cytek Biosciences
Average 93 stars, based on 1 article reviews
0454 total leukocytes - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
anti-cd45.2 bv510  (Becton Dickinson)
90
Becton Dickinson anti-cd45.2 bv510
Phenotype and immunostimulatory activity of renal mononuclear phagocytes. (A) Representative contour plot for CD11c (APC-Cy7) and F4/80 (APC) expression on pregated <t>CD45+</t> renal single cells. (B) Representative contour plots for IRF4 (FITC) and IRF8 (PE) staining on pregated CD11c−F4/80+CD45+, CD11c+F4/80+CD45+, and CD11c+F4/80−CD45+ renal single cells. (C) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to CD11c−F4/80+, CD11c+F4/80+, or CD11c+F4/80− cells isolated from C57/BL6 kidneys. Mean±SD of three replicates from one representative experiment, *P<0.05. (D) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells either unstimulated or LPS-stimulated; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ (TH1 or TH17) or OT1-CD8+ (TC1 or TC17) T cell clones detected by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells (OVA-transgenic or wild-type). Wild-type renal CD11c+F4/80+ cells were exposed or not to OVA, either in vitro (100 μg/ml) during MLR or in vivo by intravenous infusion (1mg/500 μl per mouse). OVA-exposed (both in vitro and in vivo) renal CD11c+F4/80+ cells were either stimulated with LPS or left unstimulated during the MLR. Values are mean±SD, n=3–4 independent experiments for each condition; *P<0.05. ND, not detectable.
Anti Cd45.2 Bv510, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd45.2 bv510/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd45.2 bv510 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
goat anti-mouse ig-hrp  (SouthernBiotech)
90
SouthernBiotech goat anti-mouse ig-hrp
Phenotype and immunostimulatory activity of renal mononuclear phagocytes. (A) Representative contour plot for CD11c (APC-Cy7) and F4/80 (APC) expression on pregated <t>CD45+</t> renal single cells. (B) Representative contour plots for IRF4 (FITC) and IRF8 (PE) staining on pregated CD11c−F4/80+CD45+, CD11c+F4/80+CD45+, and CD11c+F4/80−CD45+ renal single cells. (C) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to CD11c−F4/80+, CD11c+F4/80+, or CD11c+F4/80− cells isolated from C57/BL6 kidneys. Mean±SD of three replicates from one representative experiment, *P<0.05. (D) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells either unstimulated or LPS-stimulated; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ (TH1 or TH17) or OT1-CD8+ (TC1 or TC17) T cell clones detected by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells (OVA-transgenic or wild-type). Wild-type renal CD11c+F4/80+ cells were exposed or not to OVA, either in vitro (100 μg/ml) during MLR or in vivo by intravenous infusion (1mg/500 μl per mouse). OVA-exposed (both in vitro and in vivo) renal CD11c+F4/80+ cells were either stimulated with LPS or left unstimulated during the MLR. Values are mean±SD, n=3–4 independent experiments for each condition; *P<0.05. ND, not detectable.
Goat Anti Mouse Ig Hrp, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti-mouse ig-hrp/product/SouthernBiotech
Average 90 stars, based on 1 article reviews
goat anti-mouse ig-hrp - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
apc- cd45.2  (Thermo Fisher)
90
Thermo Fisher apc- cd45.2
Histological evaluation of jejunum and immune cells involved in innate immunity in LPL of small intestine. (A) Representative images of HE- and PAS-stained, GFP-positive, and Muc2-immunostained jejunum sections. Jejunum tissue was collected at 12 wk of age. In the GFP fluorescence image, MPs are enlarged and indicated by arrows. The scale bars show 100 μ m ( 50 μ m for Muc2 image). (B) Villus height ( n = 10 ). (C) Villus width ( n = 10 ). (D) Crypt depth ( n = 10 ). (E) Total goblet cells/area ( mm 2 of jejunum) ( n = 10 ). (F) Mucus layer thickness ( n = 10 ). (G) GFP-positive area ( n = 10 ). Ratio of (H) ILC1s to <t>CD45-positive</t> cells, (I) T-bet positive ILC3s to CD45-positive cells, (J) M1 macrophages to M2 macrophages in the small intestine, and (K) ILC3s to CD45-positive cells ( n = 10 in each case). Data are presented as mean ± SD values. Data were analyzed using one-way ANOVA with Holm-Šídák’s multiple comparisons test. Summary data can be found in Table S2. * p < 0.05 , ** p < 0.01 , *** p < 0.001 , and **** p < 0.0001 . Note: ANOVA, analysis of variance; GFP, green fluorescent protein; H&E, hematoxylin and eosin; HFD, high-fat diet; ILCs, innate lymphoid cells; MPs, microplastics; ND, normal diet; PAS, periodic acid Schiff; SD, standard deviation.
Apc Cd45.2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc- cd45.2/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
apc- cd45.2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from CD45 congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, CD45.2) and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).

Journal: Immunity

Article Title: A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf to orchestrate T follicular helper differentiation.

doi: 10.1016/j.immuni.2019.06.023

Figure Lengend Snippet: (A) Contour plots show Cxcr5 vs. PD1 expression at d7 p.i. on gp66-specific host cells (left) and Smarta donor cells (right two plots) from CD45 congenic WT recipients of Zbtb7bPD or control Smarta T cells. Contour plots are representative of 2 experiments totaling n=6 (Ctrl) or 7 (Zbtb7bPD) mice, summarized in graph (right). (B) Numbers of host Tfh and GC B cells in experiments shown in (A). (C, D) Adoptively transferred Smarta cells were analyzed as in (A) at d3 p.i. (C) Contour plots (top) are representative of 4 experiments; graphs (bottom) show percent and absolute numbers of Cxcr5+ cells from one representative experiment with 3 mice of each genotype. (D) Graphs show MFI of intra-cellular Nur77, and surface CD69 and PD-1 expression on Smarta cells at d3 p.i. (left) and on indicated CD4+ T cell subsets from uninfected wild-type mice as a reference (right). (E) Mixed chimeras made from either Zbtb7bAD or control (‘tester’, CD45.2) and wild-type CD45.1 competitor bone marrow were assessed for Tfh and GC B differentiation. Graphs show numbers of cells of tester origin (Zbtb7bAD or control as indicated): (left) total (bottom) and Cxcr5+PD-1hi Tfh (top) gp66-specific CD4+ T cells, (right) total (bottom) and Fas+GL7+IgDlo B220+ GC B (top) B cells. Data is from 2 independent experiments including a total of 5 chimera each with control or Zbtb7bAD tester marrow; ****p<0.0001, **P< 0.003, *P<0.02 (Student t-test).

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-B220-V500 (Clone RA3-6B2) BD Pharmigen Cat# 561227, RRID:AB_10562193 Anti-CXCR5-PE-eFluor 610 (Clone SPRCL5) Thermofisher Cat# 61-7185-82, RRID:AB_2574660 Anti-Thpok-AF647 (Clone T43-94) BD Pharmigen Cat# 565500, RRID:AB_273926 Anti-CD4-BV786 BD Pharmigen Cat# 563727, RRID:AB_2728707 Anti-CD4-PE Thermofisher Cat# 12-0043-85, RRID:AB_465516 Anti-CD40L-PE Thermofisher Cat# 17-1541-82, RRID:AB_795823 Anti-TCRb-e450 Thermofisher Cat# 48-5961-82, RRID:AB_11039532 Anti-Thy1.1-PECy7 Thermofisher Cat# 25-0900-82, RRID:AB_469640 Anti-Thy1.1-e450 Thermofisher Cat# 561406, RRID:AB_10680271 Anti-CD44-e450 Thermofisher Cat# 48-0441-82, RRID:AB_1272246 Anti-CD44-AF700 Thermofisher Cat# 56-0441-82, RRID:AB_494011 Anti-PD-1-PECy7 Thermofisher Cat# 25-9985-82, RRID:AB_10853805 Anti-GL7-e450 Thermofisher Cat# 48-5902-80, RRID:AB_10854881 Anti-IgD-APC Thermofisher Cat# 17-5993-80, RRID:AB_10598656 Anti-Fas-PE Thermofisher Cat# 554258, RRID:AB_395330 Anti-Bcl6-PE Thermofisher Cat# 561522, RRID:AB_10717126 Anti TCF-1 Cell Signaling Technologies Cat# 2203, RRID:AB_2199302 Goat-Anti Rabbit IgG F(ab’)2 Jackson Immunoresearch Laboratories Cat# 111-136-144, RRID:AB_2337987 Anti-CD4-APC-e780 Thermofisher Cat# 47-0042-82, RRID:AB_1272183 Anti-CD8a PerCP-CY5.5 Thermofisher Cat# 45-0081-82, RRID:AB_1107004 Anti-CD45.1-AF780 Thermofisher Cat# 47-0453-82, RRID:AB_1582228 Anti-CD45.2-PerCP-Cy5.5 Thermofisher Cat# 45-0454-82, RRID:AB_953590 Anti-Nur77-PE Thermofisher Cat# 12-5965-80, RRID:AB_1257210 Anti-CD69-PE Thermofisher Cat# 12-0691-82, RRID:AB_465732 Anti-CD45.2- V500 Thermofisher Cat# 562129, RRID:AB_10897142 Anti-CD45.2- BV786 Thermofisher Cat# 563686, RRID:AB_2738375 Anti-IgD-AF647 Biolegend Cat# 405708, RRID:AB_893528 goat anti-IgG-HRP Southern Biotech Cat# 1031-05, RRID:AB_2794307 anti-CD3 (2C11) BioXcell Cat# BE0001-1, RRID:AB_1107634 anti-CD28 (37.51) BioXcell Cat# BE0015-1, RRID:AB_1107624 Bacterial and Virus Strains LCMV Armstrong McGavern Lab Generated in house Biological Samples Toxoplasma gondii M.E.

Techniques: Expressing

KEY RESOURCES TABLE

Journal: Immunity

Article Title: A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf to orchestrate T follicular helper differentiation.

doi: 10.1016/j.immuni.2019.06.023

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-B220-V500 (Clone RA3-6B2) BD Pharmigen Cat# 561227, RRID:AB_10562193 Anti-CXCR5-PE-eFluor 610 (Clone SPRCL5) Thermofisher Cat# 61-7185-82, RRID:AB_2574660 Anti-Thpok-AF647 (Clone T43-94) BD Pharmigen Cat# 565500, RRID:AB_273926 Anti-CD4-BV786 BD Pharmigen Cat# 563727, RRID:AB_2728707 Anti-CD4-PE Thermofisher Cat# 12-0043-85, RRID:AB_465516 Anti-CD40L-PE Thermofisher Cat# 17-1541-82, RRID:AB_795823 Anti-TCRb-e450 Thermofisher Cat# 48-5961-82, RRID:AB_11039532 Anti-Thy1.1-PECy7 Thermofisher Cat# 25-0900-82, RRID:AB_469640 Anti-Thy1.1-e450 Thermofisher Cat# 561406, RRID:AB_10680271 Anti-CD44-e450 Thermofisher Cat# 48-0441-82, RRID:AB_1272246 Anti-CD44-AF700 Thermofisher Cat# 56-0441-82, RRID:AB_494011 Anti-PD-1-PECy7 Thermofisher Cat# 25-9985-82, RRID:AB_10853805 Anti-GL7-e450 Thermofisher Cat# 48-5902-80, RRID:AB_10854881 Anti-IgD-APC Thermofisher Cat# 17-5993-80, RRID:AB_10598656 Anti-Fas-PE Thermofisher Cat# 554258, RRID:AB_395330 Anti-Bcl6-PE Thermofisher Cat# 561522, RRID:AB_10717126 Anti TCF-1 Cell Signaling Technologies Cat# 2203, RRID:AB_2199302 Goat-Anti Rabbit IgG F(ab’)2 Jackson Immunoresearch Laboratories Cat# 111-136-144, RRID:AB_2337987 Anti-CD4-APC-e780 Thermofisher Cat# 47-0042-82, RRID:AB_1272183 Anti-CD8a PerCP-CY5.5 Thermofisher Cat# 45-0081-82, RRID:AB_1107004 Anti-CD45.1-AF780 Thermofisher Cat# 47-0453-82, RRID:AB_1582228 Anti-CD45.2-PerCP-Cy5.5 Thermofisher Cat# 45-0454-82, RRID:AB_953590 Anti-Nur77-PE Thermofisher Cat# 12-5965-80, RRID:AB_1257210 Anti-CD69-PE Thermofisher Cat# 12-0691-82, RRID:AB_465732 Anti-CD45.2- V500 Thermofisher Cat# 562129, RRID:AB_10897142 Anti-CD45.2- BV786 Thermofisher Cat# 563686, RRID:AB_2738375 Anti-IgD-AF647 Biolegend Cat# 405708, RRID:AB_893528 goat anti-IgG-HRP Southern Biotech Cat# 1031-05, RRID:AB_2794307 anti-CD3 (2C11) BioXcell Cat# BE0001-1, RRID:AB_1107634 anti-CD28 (37.51) BioXcell Cat# BE0015-1, RRID:AB_1107624 Bacterial and Virus Strains LCMV Armstrong McGavern Lab Generated in house Biological Samples Toxoplasma gondii M.E.

Techniques: Generated, Recombinant, Purification, Staining, Plasmid Preparation, Reporter Assay, Expressing, Transduction, Transgenic Assay, Software

Phenotype and immunostimulatory activity of renal mononuclear phagocytes. (A) Representative contour plot for CD11c (APC-Cy7) and F4/80 (APC) expression on pregated CD45+ renal single cells. (B) Representative contour plots for IRF4 (FITC) and IRF8 (PE) staining on pregated CD11c−F4/80+CD45+, CD11c+F4/80+CD45+, and CD11c+F4/80−CD45+ renal single cells. (C) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to CD11c−F4/80+, CD11c+F4/80+, or CD11c+F4/80− cells isolated from C57/BL6 kidneys. Mean±SD of three replicates from one representative experiment, *P<0.05. (D) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells either unstimulated or LPS-stimulated; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ (TH1 or TH17) or OT1-CD8+ (TC1 or TC17) T cell clones detected by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells (OVA-transgenic or wild-type). Wild-type renal CD11c+F4/80+ cells were exposed or not to OVA, either in vitro (100 μg/ml) during MLR or in vivo by intravenous infusion (1mg/500 μl per mouse). OVA-exposed (both in vitro and in vivo) renal CD11c+F4/80+ cells were either stimulated with LPS or left unstimulated during the MLR. Values are mean±SD, n=3–4 independent experiments for each condition; *P<0.05. ND, not detectable.

Journal: Journal of the American Society of Nephrology : JASN

Article Title: Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c + F4/80 + Macrophages through IL-1R8 Regulation

doi: 10.1681/ASN.2019080778

Figure Lengend Snippet: Phenotype and immunostimulatory activity of renal mononuclear phagocytes. (A) Representative contour plot for CD11c (APC-Cy7) and F4/80 (APC) expression on pregated CD45+ renal single cells. (B) Representative contour plots for IRF4 (FITC) and IRF8 (PE) staining on pregated CD11c−F4/80+CD45+, CD11c+F4/80+CD45+, and CD11c+F4/80−CD45+ renal single cells. (C) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to CD11c−F4/80+, CD11c+F4/80+, or CD11c+F4/80− cells isolated from C57/BL6 kidneys. Mean±SD of three replicates from one representative experiment, *P<0.05. (D) Frequency of IFN-γ+ and IL-17+ alloreactive Balb/c T cells by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells either unstimulated or LPS-stimulated; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ (TH1 or TH17) or OT1-CD8+ (TC1 or TC17) T cell clones detected by ELISpot after 2 days of exposure to renal CD11c+F4/80+ cells (OVA-transgenic or wild-type). Wild-type renal CD11c+F4/80+ cells were exposed or not to OVA, either in vitro (100 μg/ml) during MLR or in vivo by intravenous infusion (1mg/500 μl per mouse). OVA-exposed (both in vitro and in vivo) renal CD11c+F4/80+ cells were either stimulated with LPS or left unstimulated during the MLR. Values are mean±SD, n=3–4 independent experiments for each condition; *P<0.05. ND, not detectable.

Article Snippet: Total cells obtained after kidney digestion or microbead-enriched cells, as appropriate, were resuspended in FACS buffer (PBS/FBS 2%) and stained for 30 minutes with fluorochrome-conjugated anti-CD45.1 PE (A20; BD Biosciences), anti-CD45.1 AF488 (A20; BioLegend), anti-CD45.2 PE (104; BioLegend), anti-CD45.2 FITC (104; BD Biosciences), anti-CD45.2 BV510 (104; BD Biosciences), anti-F4/80 APC (CI:A3–1; Bio-Rad), anti-CD11c APC-Cy7 (N418; Tonbo), anti-class II MHC I-A/I-E FITC (2G9; BD Biosciences), anti–Ki-67 PE (SolA15; Thermo Fisher), anti-CD206 BV421 (CO68CZ; BD Biosciences), or anti-CD38 FITC (90; eBioscience).

Techniques: Activity Assay, Expressing, Staining, Enzyme-linked Immunospot, Isolation, Clone Assay, Transgenic Assay, In Vitro, In Vivo

CI injury modifies the phenotype and the immunostimulatory activity of renal CD11c+F4/80+ MΦs. (A) Cell counts of CD11c+F4/80+CD45+, CD11c+F4/80−CD45+, and CD11c−F4/80+CD45+ renal single cells from kidneys subjected or not to 16 hours of CI. Mean±SD, n=4 independent experiments; *P<0.05. (B) Log-fold change of median fluorescence intensity (MFI) of different markers on CD11c+F4/80+ rMΦs from kidneys subjected to CI compared with nonischemic kidneys. Mean±SD, n=3–4 independent experiments for each molecule; *P<0.05 versus pre-CI MFI. (C) T cell proliferation (3H-thymidine incorporation) of alloreactive Balb/c T cells after 2 days of exposure to CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours of CI. Values are the three replicates of a representative experiment; *P<0.05. (D) Representative images and results summary of IFN-γ+ and IL-17+ alloreactive Balb/c T cell frequency assessed by ELISpot after 2 days of exposure to renal CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours CI and used either unstimulated or LPS-stimulated. Mean±SD, n=7 independent experiments for IFN-γ+ and n=4 independent experiments for IL-17+; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ or OT1-CD8+ T cells by ELISpot after 2 days of exposure to CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours CI. Renal CD11c+F4/80+ rMΦs were exposed to OVA in vivo by intravenous infusion and used either unstimulated or LPS-stimulated in vitro during MLR. Mean±SD, n=3–5 independent experiments for each condition; *P<0.05.

Journal: Journal of the American Society of Nephrology : JASN

Article Title: Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c + F4/80 + Macrophages through IL-1R8 Regulation

doi: 10.1681/ASN.2019080778

Figure Lengend Snippet: CI injury modifies the phenotype and the immunostimulatory activity of renal CD11c+F4/80+ MΦs. (A) Cell counts of CD11c+F4/80+CD45+, CD11c+F4/80−CD45+, and CD11c−F4/80+CD45+ renal single cells from kidneys subjected or not to 16 hours of CI. Mean±SD, n=4 independent experiments; *P<0.05. (B) Log-fold change of median fluorescence intensity (MFI) of different markers on CD11c+F4/80+ rMΦs from kidneys subjected to CI compared with nonischemic kidneys. Mean±SD, n=3–4 independent experiments for each molecule; *P<0.05 versus pre-CI MFI. (C) T cell proliferation (3H-thymidine incorporation) of alloreactive Balb/c T cells after 2 days of exposure to CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours of CI. Values are the three replicates of a representative experiment; *P<0.05. (D) Representative images and results summary of IFN-γ+ and IL-17+ alloreactive Balb/c T cell frequency assessed by ELISpot after 2 days of exposure to renal CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours CI and used either unstimulated or LPS-stimulated. Mean±SD, n=7 independent experiments for IFN-γ+ and n=4 independent experiments for IL-17+; *P<0.05. (E and F) Frequency of IFN-γ+ (E) and IL-17+ (F) OVA-specific OT2-CD4+ or OT1-CD8+ T cells by ELISpot after 2 days of exposure to CD11c+F4/80+ rMΦs isolated from kidneys subjected or not to 16 hours CI. Renal CD11c+F4/80+ rMΦs were exposed to OVA in vivo by intravenous infusion and used either unstimulated or LPS-stimulated in vitro during MLR. Mean±SD, n=3–5 independent experiments for each condition; *P<0.05.

Article Snippet: Total cells obtained after kidney digestion or microbead-enriched cells, as appropriate, were resuspended in FACS buffer (PBS/FBS 2%) and stained for 30 minutes with fluorochrome-conjugated anti-CD45.1 PE (A20; BD Biosciences), anti-CD45.1 AF488 (A20; BioLegend), anti-CD45.2 PE (104; BioLegend), anti-CD45.2 FITC (104; BD Biosciences), anti-CD45.2 BV510 (104; BD Biosciences), anti-F4/80 APC (CI:A3–1; Bio-Rad), anti-CD11c APC-Cy7 (N418; Tonbo), anti-class II MHC I-A/I-E FITC (2G9; BD Biosciences), anti–Ki-67 PE (SolA15; Thermo Fisher), anti-CD206 BV421 (CO68CZ; BD Biosciences), or anti-CD38 FITC (90; eBioscience).

Techniques: Activity Assay, Fluorescence, Isolation, Enzyme-linked Immunospot, In Vivo, In Vitro

Donor CD11c+F4/80+ rMΦs cell count and phenotype in transplantation-induced I/RI. (A and B) Cell counts of total donor cells (CD45.2+), donor rMΦs (CD45.2+CD11c+F4/80+), total recipient cells (CD45.1+), and recipient rMΦs (CD45.1+CD11c+F4/80+) in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts pretransplant (pre-tx) and at days 1, 3–4, and 7–10 post-transplant. Mean±SD, n=3–7 mice at each time point; *P<0.05 versus pre-tx, ND: not detectable. (C) Percentage of proliferating (Ki67+) cells on donor rMΦs in wild-type kidney grafts pretransplant and at days 1–3 and 7–10 post-transplant. Mean±SD, n=2–3 mice at each time point; *P<0.05 versus pre-tx. (D and E) Post-transplant log-fold change in median fluorescence intensity (MFI) of selected molecules in donor rMΦs compared with pretransplant values, both in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at days 1–3 (D) and 3–7 (E) post-transplantation. Mean±SD, n=2–6 mice for each molecule at each time point; *P<0.05. (F) iNOS, TNFα, and Ym1 mRNA expression in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at day 7 post-transplant. Mean±SD, n=3–4 mice; *P<0.05. (G) Semiquantitative scores (0–3) and representative images of nitro-tyrosine staining in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at day 7 post-transplant. *P<0.05. Original magnification, ×400.

Journal: Journal of the American Society of Nephrology : JASN

Article Title: Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c + F4/80 + Macrophages through IL-1R8 Regulation

doi: 10.1681/ASN.2019080778

Figure Lengend Snippet: Donor CD11c+F4/80+ rMΦs cell count and phenotype in transplantation-induced I/RI. (A and B) Cell counts of total donor cells (CD45.2+), donor rMΦs (CD45.2+CD11c+F4/80+), total recipient cells (CD45.1+), and recipient rMΦs (CD45.1+CD11c+F4/80+) in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts pretransplant (pre-tx) and at days 1, 3–4, and 7–10 post-transplant. Mean±SD, n=3–7 mice at each time point; *P<0.05 versus pre-tx, ND: not detectable. (C) Percentage of proliferating (Ki67+) cells on donor rMΦs in wild-type kidney grafts pretransplant and at days 1–3 and 7–10 post-transplant. Mean±SD, n=2–3 mice at each time point; *P<0.05 versus pre-tx. (D and E) Post-transplant log-fold change in median fluorescence intensity (MFI) of selected molecules in donor rMΦs compared with pretransplant values, both in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at days 1–3 (D) and 3–7 (E) post-transplantation. Mean±SD, n=2–6 mice for each molecule at each time point; *P<0.05. (F) iNOS, TNFα, and Ym1 mRNA expression in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at day 7 post-transplant. Mean±SD, n=3–4 mice; *P<0.05. (G) Semiquantitative scores (0–3) and representative images of nitro-tyrosine staining in wild-type (IL-1R8+/+) and IL-1R8−/− kidney grafts at day 7 post-transplant. *P<0.05. Original magnification, ×400.

Article Snippet: Total cells obtained after kidney digestion or microbead-enriched cells, as appropriate, were resuspended in FACS buffer (PBS/FBS 2%) and stained for 30 minutes with fluorochrome-conjugated anti-CD45.1 PE (A20; BD Biosciences), anti-CD45.1 AF488 (A20; BioLegend), anti-CD45.2 PE (104; BioLegend), anti-CD45.2 FITC (104; BD Biosciences), anti-CD45.2 BV510 (104; BD Biosciences), anti-F4/80 APC (CI:A3–1; Bio-Rad), anti-CD11c APC-Cy7 (N418; Tonbo), anti-class II MHC I-A/I-E FITC (2G9; BD Biosciences), anti–Ki-67 PE (SolA15; Thermo Fisher), anti-CD206 BV421 (CO68CZ; BD Biosciences), or anti-CD38 FITC (90; eBioscience).

Techniques: Cell Counting, Transplantation Assay, Fluorescence, Expressing, Staining

Histological evaluation of jejunum and immune cells involved in innate immunity in LPL of small intestine. (A) Representative images of HE- and PAS-stained, GFP-positive, and Muc2-immunostained jejunum sections. Jejunum tissue was collected at 12 wk of age. In the GFP fluorescence image, MPs are enlarged and indicated by arrows. The scale bars show 100 μ m ( 50 μ m for Muc2 image). (B) Villus height ( n = 10 ). (C) Villus width ( n = 10 ). (D) Crypt depth ( n = 10 ). (E) Total goblet cells/area ( mm 2 of jejunum) ( n = 10 ). (F) Mucus layer thickness ( n = 10 ). (G) GFP-positive area ( n = 10 ). Ratio of (H) ILC1s to CD45-positive cells, (I) T-bet positive ILC3s to CD45-positive cells, (J) M1 macrophages to M2 macrophages in the small intestine, and (K) ILC3s to CD45-positive cells ( n = 10 in each case). Data are presented as mean ± SD values. Data were analyzed using one-way ANOVA with Holm-Šídák’s multiple comparisons test. Summary data can be found in Table S2. * p < 0.05 , ** p < 0.01 , *** p < 0.001 , and **** p < 0.0001 . Note: ANOVA, analysis of variance; GFP, green fluorescent protein; H&E, hematoxylin and eosin; HFD, high-fat diet; ILCs, innate lymphoid cells; MPs, microplastics; ND, normal diet; PAS, periodic acid Schiff; SD, standard deviation.

Journal: Environmental Health Perspectives

Article Title: Oral Exposure to Polystyrene Microplastics of Mice on a Normal or High-Fat Diet and Intestinal and Metabolic Outcomes

doi: 10.1289/EHP11072

Figure Lengend Snippet: Histological evaluation of jejunum and immune cells involved in innate immunity in LPL of small intestine. (A) Representative images of HE- and PAS-stained, GFP-positive, and Muc2-immunostained jejunum sections. Jejunum tissue was collected at 12 wk of age. In the GFP fluorescence image, MPs are enlarged and indicated by arrows. The scale bars show 100 μ m ( 50 μ m for Muc2 image). (B) Villus height ( n = 10 ). (C) Villus width ( n = 10 ). (D) Crypt depth ( n = 10 ). (E) Total goblet cells/area ( mm 2 of jejunum) ( n = 10 ). (F) Mucus layer thickness ( n = 10 ). (G) GFP-positive area ( n = 10 ). Ratio of (H) ILC1s to CD45-positive cells, (I) T-bet positive ILC3s to CD45-positive cells, (J) M1 macrophages to M2 macrophages in the small intestine, and (K) ILC3s to CD45-positive cells ( n = 10 in each case). Data are presented as mean ± SD values. Data were analyzed using one-way ANOVA with Holm-Šídák’s multiple comparisons test. Summary data can be found in Table S2. * p < 0.05 , ** p < 0.01 , *** p < 0.001 , and **** p < 0.0001 . Note: ANOVA, analysis of variance; GFP, green fluorescent protein; H&E, hematoxylin and eosin; HFD, high-fat diet; ILCs, innate lymphoid cells; MPs, microplastics; ND, normal diet; PAS, periodic acid Schiff; SD, standard deviation.

Article Snippet: We used the following antibodies for gating of M1 and M2 macrophages: FITC-CD206 (MA516870; clone: MR5D3, 1/50, eBioscience, Inc.), PE-F4/80 (12,480,182; clone: BM8, 1/50, eBioscience, Inc.), APC- CD45.2 (17,045,482; clone: 104, 1/50; eBioscience, Inc.), PE-Cy7-CD11c (25,011,482; clone: N418, 1/50, eBioscience, Inc.), and APC-Cy7-CD11b (47,011,282; clone: M1/70, 1/50; eBioscience, Inc.) (Figure S2).

Techniques: Staining, Fluorescence, Standard Deviation